Biotinylated Human HGF R / c-MET Protein, Avitag?,His Tag (MALS verified)

分子別名（Synonym）

MET,AUTS9,HGFR,RCCP2,c-Met

表達區(qū)間及表達系統(tǒng)（Source）

Biotinylated Human HGF R, Avitag,His Tag (MET-H82E1) is expressed from human 293 cells (HEK293). It contains AA Glu 25 - Thr 932 (Accession # P08581-1).

Predicted N-terminus: Glu 25 (α chain) & Ser 308 (β chain)

蛋白結(jié)構(gòu)（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).

The protein has a calculated MW of 32.5 kDa (α chain) & 72.7 kDa (β chain). The protein migrates as 40-50 kDa (α subunit) and 90-100 kDa (β subunit) when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

標(biāo)記（Labeling）

Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白標(biāo)記度（Protein Ratio）

Passed as determined by the HABA assay / binding ELISA.

內(nèi)毒素（Endotoxin）

Less than 1.0 EU per μg by the LAL method / rFC method.

純度（Purity）

>90% as determined by SDS-PAGE.

制劑（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重構(gòu)方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存儲（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景介紹

肝細(xì)胞生長因子受體（HGFR）又稱間質(zhì)-上皮轉(zhuǎn)化因子（MET）或c-Met，是一種糖基化受體酪氨酸激酶，在上皮形態(tài)發(fā)生和癌癥發(fā)展中起核心調(diào)控作用。該受體具有酪氨酸激酶活性，其前體單鏈蛋白經(jīng)翻譯后剪切形成α與β亞基，通過二硫鍵連接組成成熟受體。HGFR通常表達于上皮源性細(xì)胞，而其配體HGF僅由間質(zhì)源性細(xì)胞產(chǎn)生。當(dāng)HGF刺激時，HGFR誘導(dǎo)的系列生物學(xué)反應(yīng)共同啟動"侵襲性生長"程序。該受體在癌癥中的異?；罨c不良預(yù)后相關(guān)：失控的HGFR信號會觸發(fā)腫瘤增殖、促進營養(yǎng)供給性血管新生、并導(dǎo)致癌癥遠(yuǎn)處轉(zhuǎn)移（轉(zhuǎn)移）。HGFR在腎癌、肝癌、胃癌、乳腺癌及腦瘤等多種惡性腫瘤中呈現(xiàn)異常活化。正常情況下僅干細(xì)胞與祖細(xì)胞表達HGFR，而腫瘤干細(xì)胞被認(rèn)為劫持了正常干細(xì)胞表達HGFR的能力，成為癌癥持續(xù)存在及全身轉(zhuǎn)移的根源。HGFR基因的多種突變與乳頭狀腎細(xì)胞癌相關(guān)，其介導(dǎo)的侵襲性生長程序可同時觸發(fā)細(xì)胞增殖與形態(tài)發(fā)生。